ACTRIMS Forum 2021 - E-Posters

The ACTRIMS Forum 2021, themed The Spectrum of Multiple Sclerosis, took place virtually February 25-27, 2021. The ACTRIMS Forum is an annual translational science meeting highlighting novel and rigorous scientific discoveries made in MS that advance our understanding of research and clinical care of MS patients.

Course Details

Clinical Outcome Measures, Biosensors, Biomarkers and Bioinformatics
P009. A Multicenter Evaluation of the Diagnostic Performance of the Central Vein Sign Using Simplified Algorithms
P010. Analytical Validation of a Multivariate Proteomic Serum Based Assay for Disease Activity Assessments in MS
P012. Cerebrospinal Fluid Clinical Profile is Similar Between African American and Caucasian Multiple Sclerosis Patients
P013. Changes in Peripheral Blood Cells with Teriflunomide and Treatment Response
P014. Clinical Validation of a Multivariate Proteomic Serum Based Assay for Disease Activity Assessments in MS
P015. Correlations of Serum Neurofilaments with Myelin, Axonal and Volumetric Imaging Across the Multiple Sclerosis Spectrum
P016. Cryopreservation of Cerebrospinal Fluid CSF Derived-Cells: A Novel Approach for Intrathecal Investigation
P017. Early Reduction in Plasma Glial Fibrillary Acidic Protein Levels in Siponimod-treated SPMS Patients (EXPAND) is Associated with Reduced Risk of Disability Worsening
P018. Effect of Fingolimod vs Interferon Treatment on OCT Measurements and Cognitive Function in RRMS
P019. Il-1 Receptor Antagonist: A Novel Soluble Biomarker that Correlates With Disability and Neurofilament Light in Multiple Sclerosis
P020. Integrated Analysis of Novel MRI and Blood Serum Biomarkers for the Estimation and Prediction of MS Disease Activity and Progression
P021. Modeling and Simulation Comparison of Pharmacokinetics and Pharmacodynamics of Natalizumab Every 6 Weeks Following Subcutaneous and Intravenous Dosing
P022. Modulation of Retinal Atrophy With Dimethyl Fumarate in Multiple Sclerosis
P023. Neurodegenerative and Inflammatory Biomarkers in the Cerebrospinal Fluid of Patients with Multiple Sclerosis: a Network-Based Approach
P024. Pharmacokinetics and Pharmacodynamics of Natalizumab Every 4 Weeks Following Subcutaneous and Intravenous Administration
P025. Proteomic Serum Biomarker Signatures Associated with Patient Reported Outcomes in Multiple Sclerosis
P026. Treatment-Induced Reductions in Cerebrospinal Fluid Neurofilament Light Levels Are Age-Dependent in Multiple Sclerosis
P027. Feasibility of Postural Sway Measures to Predict Falls in Multiple Sclerosis
P028. Dimethyl Fumarate to Diroximel Fumarate Switch: Safety and Efficacy Findings from the Phase 3 EVOLVE-MS-1 Study
P029. Disability Measure in Mexican Multiple Sclerosis Patients
P030. DISCO-MS Survey of Disclosure and Concealment in MS: I. Prevalence and Demographics
P031. DISCO-MS Survey of Disclosure and Concealment in MS: II. Associations with Anxiety and Depression
P032. Efficacy and Safety Outcomes Post-Dimethyl Fumarate Discontinuation in ESTEEM
P033. Electronic Pill Bottle Monitoring to Promote Medication Adherence for People with Multiple Sclerosis: A Randomized Virtual Clinical Trial
P034. MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and Without Disease Activity
P035. Predictive Value of NEDA for Long-Term Disability in Multiple Sclerosis Observational Studies: A Systematic Review and Meta-Analysis
P036. Prevalence of Depression in Patients with Multiple Sclerosis (MS) Treated at the Neuro-Psychiatric Center in Riem (NPZR)
P037. Smartphone-Based Symbol-Digit Modalities Test Reliably Captures Brain Damage in Multiple Sclerosis
P038. Upper Cervical Spinal Cord Volume Predicts Multiple Sclerosis Clinical Outcome Much Stronger Than Brain Volumes
Clinical Trials
P039. Applying the COM-B Model to Identify Behaviors & Factors for Multiple Sclerosis Fatigue Management
P040. A First-in-Class CXCR7 Antagonist Increases Plasma concentrations of the target engagement biomarker CXCL12 in a multi-purpose first-in-human study
P041. Disease-Modifying Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Comparison of Their Efficacy for Reducing Relapse Rate
P042. Effectiveness, Safety and Patient-reported Outcomes of Ofatumumab in Relapsing Multiple Sclerosis Patients Switching from Dimethyl Fumarate or Fingolimod: ARTIOS Phase 3b Study Design
P043. Effects of Nanocatalysis on CNS Bioenergetic Markers in Patients Treated with CNM-Au8: Interim Results from Two Phase 231Phosphorous Imaging Studies
P044. Effects of Wahls Elimination and Swank Dietary Patterns on Motor Functions and Mood of Individuals with Multiple Sclerosis
P045. Efficacy and Safety Outcomes After Transition From Glatiramer Acetate to Diroximel Fumarate: Results From the Phase 3 EVOLVE-MS-1 Study
P046. Efficacy of Ozanimod by Baseline EDSS Score in RMS: A Post Hoc, Exploratory Analysis of Pooled Data from Phase 3 Ozanimod Trials
P047. Nutritional Adequacy of the Swank and Wahls Diets Among Relapsing-Remitting Multiple Sclerosis: An Analysis of Weighed Food Records
P048. Phase I, Multicenter, Two-Part Study of ATA188, an Open-Label, Dose-Escalation and Double-Blind, Placebo-Controlled Dose-Expansion Study
P049. Tolerability of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis Patients with Gastrointestinal Comorbidities at Baseline
P050. VISIONARY-MS: Update to a Phase 2 Clinical Trial of Catalytic Gold Nanocrystals, CNM-Au8, for the Treatment of Chronic Optic Neuropathy
Disease Modifying Therapies
P059. Analysis of Influenza and Varicella Zoster Virus Vaccine Antibody Titers in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets
P060. Analysis of Lymphocyte Subsets in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets
P061. B-Cell Subset Depletion Following Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis
P062. Effect of Switching Glatiramer Acetate Formulation from 20 mg Daily to 40 mg Three Times Weekly on Immune Functions in RRMS
P063. Impact of B Cell-Depletion on Plasma Cells in a Pre-Clinical Model of Meningeal Inflammation and Subpial Demyelination
P064. Ocrelizumab Treatment Decreases the Cellular Immune Response to Autologous Epstein-Barr Virus Infected Cells
P065. Single-cell RNA-sequencing of RRMS Cerebrospinal Fluid Identifies Changes in Cell Type Proportions Following Reconstitution After Natalizumab Treatment
P066. The Anti-Inflammatory and Neuroprotective Effects of NLY01, A Novel Glucagon-like Peptide-1 Receptor Agonist, in Experimental Autoimmune Encephalomyelitis
P067. The CLADRINA Trial: Evaluating Treatment with Cladribine Tablets Following Natalizumab
P068. Analysis of Infection in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets who had Grade ≥3 Lymphopenia
P069. Analysis of Ocrelizumab Treatment in Aged Patients at an Academic MS Center
P070. Emerging Cases of Severe Babesia Microti Infections in Multiple Sclerosis Patients Treated with Ocrelizumab: Report of Two Cases
P071. Evaluating The Impact Of Cladribine Tablets On The Development Of Antibody Titres: Interim Results from the CLOCK-MS Influenza Vaccine Sub-Study
P072. Evaluation of Nearly 10,000 Natalizumab Infusions at an Academic MS Center Reveals Lack of Clinically Relevant Infusion-related Safety Events
P073. Evaluation of Ocrelizumab in Older Progressive Multiple Sclerosis Patients
P074. Factors Impacting Disease Modifying Therapy Transition in Relapsing Remitting Multiple Sclerosis
P075. Longitudinal Adherence Trajectories of Patients with Multiple Sclerosis Initiating Once- or Twice-Daily Oral Disease-Modifying Therapies
P076. Observations Regarding Ocrelizumab use at a Tertiary Referral MS Center
P077. Patient Preference Top Reason for Switching Back to Natalizumab From Ocrelizumab: A Relapsing Multiple Sclerosis Patient Case Series
P078. Post-Approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, With Particular Reference to Respiratory Viral Infections
P079. Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome with Dimethyl Fumarate Therapy: The Role of Acute on Chronic Lymphopenia
P080. Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis
P081. Systematic Evaluation and Modeling of Dimethy Fumarate Induced Lymphopenia in MS Cohort
P082. The FDA’s Labels for MS DMTs are Inconsistent with CDC Recommendations
P083. Treatment of MS patients with Rituximab in an Algerian Cohort
Epidemiology, Comorbidities and Prognostic Factors
P084. Comorbidity Prevalence and Relationship to Disability using EDSS Score in Puerto Rican Hispanic Multiple Sclerosis Patients Diagnosed in 2017-2019
P085. Characterizing Relapsing Remitting Multiple Sclerosis Patients with Hypertension, Hyperlipidemia, and Asthma
P086. Impact of Comorbid Post-Traumatic Stress Disorder on Outcomes in Multiple Sclerosis: A Population-Based Cohort Study
P087. MS and Sarcoidosis: a Case Series for Coexistence
P088. Long Term Trajectories of Employment Status, Work hours and Disability Pension Status After an Initial Episode of CNS Demyelination
P089. Experience in the demyelinating diseases unit of the Hospital de Clínicas - Paraguay
P090. Mendelian Randomization Provides No Evidence for a Causal Role in the Bidirectional Relationship Between Depression and Multiple Sclerosis
P091. Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)
P092. Socioeconomic Disparity Correlates with Faster Inner Retinal Layer Thickness in Multiple Sclerosis
P093. The Impact of Neighborhood-level Socioeconomic Status on Mental Health and Health-Seeking Behavior in a Multiple Sclerosis Cohort
P094. The Trend of Multiple Sclerosis Incidence, Prevalence, and DALY in East Mediterranean Region During 1990-2017 Compared to the Global and West Europe's Corresponding Values: Retrieved from the Global Burden of Diseases Data
P095. Variation in Body-Mass Index but not Waist-Hip Ratio Influences Risk for Multiple Sclerosis.
P096. Association of Early Prognostic Factors with 10-Year Brain Atrophy and Disability in Multiple Sclerosis: a Comprehensive Single Center Study
P097. Black Holes as Disability Risk Factor in Multiple Sclerosis in a Mexican Tertiary-Care Center
P098. Quantitative Susceptibility Mapping of Ring Lesions in Relapsing Remitting Multiple Sclerosis
P099. Slowly Expanding Lesions and Advanced MRI Measures in Multiple Sclerosis Patients
P102. Acceleration of Whole-Brain Myelin Mapping using Compressed SENSE
P103. An increased Normal Appearing White Matter Perfusion: a Possible Radiological Inflammatory Marker in Relapsing-remitting Multiple Sclerosis
P104. Automated Detection of Paramagnetic Rims in Multiple Sclerosis Lesions on 3T Susceptibility-based MR Imaging
P105. Axonal and Myelin Volume Fractions and Imaging G-Ratio in Pediatric MS and MOG-associated Disorders
P106. Changes in the Detection and Reporting of Clinically Relevant White Matter Lesions in MS Using FDA-Cleared Automated Software
P107. Cortical Morphometric Measures associate with Cortical Lesions and Disability in Multiple Sclerosis
P108. Diffuse White Matter Abnormalities Correlate with Atrophy in Multiple Sclerosis
P111. Evaluation of the Paramagnetic Rim Lesions in MS and Radiological Mimics of MS
P112. High Field 7 Tesla Imaging to Distinguish Multiple Sclerosis Mimics: A case of Adult Polyglucosan Body Disease
P113. Investigating Relationships Between Multi-Scale Perfusion and Myelin Integrity in Patients with Relapsing-Remitting MS
P114. Investigating Superficial White Matter Integrity in Early MS Using Machine Learning
P115. Iron Rims as an Imaging Biomarker in MS: A Systematic Mapping Review
P116. MRI Characterization of Damage in and Around Lesions in Pediatric MS and MOG-associated disorders
P117. MRI in MS Survey: Insights into Access, Understanding and Interest by People with MS
P118. Navigator-guided Motion and B0 Correction of T2*-weighted MRI Improves Multiple Sclerosis Cortical Lesion Detection
P119. Paramagnetic Rims in Treatment Naive Persons at the Time of Multiple Sclerosis Diagnosis
P120. Phase Sensitive Inversion Recovery (PSIR) can Predict the Progression of Disability in MS Patients
P121. Quantitative Gradient Echo Magnetic Resonance Imaging Reveals Greater Tissue Damage in Multiple Sclerosis Lesions with Central Vein Sign Compared to Lesions Without
P122. Quantitative MRI Reveals Mild Cervical Cord Damage in Longstanding Relapsing Multiple Sclerosis
P123. Reduced Myelin Content Preceding Acute White Matter Lesions is Associated with Permanent Tissue Loss
P124. The Central Vein Sign in Multiple Sclerosis (CAVS-MS): A North American Imaging in MS (NAIMS) Cooperative Prospective Diagnostic Biomarker Study
P125. The Central Vein Sign Profile of Newly Developing T2 or Enhancing Lesions in Multiple Sclerosis
P126. Toward the Use of Paramagnetic Rim Lesions in Proof-of-Concept Clinical Trials for Treating Chronic Inflammation in Multiple Sclerosis
P127. Vascular Disease Risk Factors in Multiple Sclerosis
Neuromyelitis Optica and Anti-MOG Disease
P131. A Case of Seronegative Myelitis Extending from the Craniocervical Junction to the Conus Medullaris
P132. A Proposed Scoring System to Guide Treatment Decision in Myelin Oligodendrocyte Glycoprotein Associated Optico-Encephalo-Myelitis
P133. Central Vein Sign and Other Radiographic Features Distinguishing MOG Antibody Disease from Multiple Sclerosis and AQP4 Antibody-Positive Neuromyelitis Optica
P134. Characteristics of Pediatric Myelin Oligodendrocyte Glycoprotein Antibody Associated Disorders and Predictors of Positive Myelin Oligodendrocyte Glycoprotein-Antibody Testing
P135. Combined Central and Peripheral Nervous System Demyelination: an Unusual Presentation of MOG Antibody Disorder
P136. Comparing Individuals with Positive and Negative Myelin Oligodendrocyte Glycoprotein Antibody in Pediatric CNS Demyelinating Disorders
P137. Efficacy and Safety of Satralizumab in Adults with AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Phase 3 SAkura Studies
P138. Evaluation Of Infusion Reactions And Infusion Times In The N-Momentum Study Of Inebilizumab For NMOSD
P139. Immunoglobulin Kinetics And Infection Risk After Long-Term Inebilizumab Treatment For NMOSD
P140. Interleukin-6 Inhibition with Tocilizumab for MOG-IgG Associated Disorder
P141. Late-Onset NMOSD
P142. Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Mediated Disease: the Difficulty of Predicting Relapses
P143. Progressive Decrease in Retinal Nerve Fiber Layer Thickness in a Myelin Oligodendrocyte Glycoprotein Antibody-Associated Pediatric Case
P144. The N-MOmentum Trial of Inebilizumab for Neuromyelitis Optica Spectrum Disorder: Long-term, Open-label Efficacy and Safety Update
P145. The Safety And Efficacy Of Inebilizumab In Those With Previous Rituximab Exposure
Observational Studies
P160. Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 Patients
P161. Does Race Disproportionately Influence Walking Dysfunction in Multiple Sclerosis?
P162. FlywheelMS: Stratification of Anxiety and Depression by MS Subtype as Captured in Digitized Health Records
P163. Identifying and Characterizing Fatigue in Patients Diagnosed with Multiple Sclerosis on Disease-Modifying Therapies Using Real World Evidence
P164. Infection Risk Associated with Multiple Sclerosis Disease Modifying Therapies: Retrospective Study from a Nationally Distributed US Cohort
P165. Long-term Outcomes of CNS Demyelination Associated with Exposure to TNFaInhibitors: a Retrospective Cohort Analysis
P166. Multiple Sclerosis Disease Modifying Therapies’ Adherence and Total Medical Costs Among Women with Maternity Services using Administrative Data
P167. Multiple Sclerosis Patients Treated with Diroximel Fumarate in the Real-World Setting have High Rates of Persistence and Adherence
P168. Prevalence and Use of Disease Modifying Therapy in Radiologically Isolated Syndrome (RIS): A Retrospective Study
P169. Risk of Specific Infections in Patients With Multiple Sclerosis Versus Matched Controls: An Analysis of Administrative Claims Data
P171. Shared Decision-Making and MRI in Multiple Sclerosis: Patient Experience, Gaps and Opportunities
P172. Telemedicine Utilization and Perceptions of Multiple Sclerosis Health Care Providers
P173. Utilization and Perception of Recently Approved Disease Modifying Therapies (DMTs) for Patients with Multiple Sclerosis (MS) Among General Neurologists
P174. Vitamin D Levels and Clinical Outcomes and Quantitative MRI Metrics in a Real-world MS Cohort
Pathogenesis and Experimental Models
P175. A Comparison of Complement System Activation between a Mouse Model of Relapsing Remitting Multiple Sclerosis and a Mouse Model of Progressive Multiple Sclerosis
P176. Ageing Promotes Non-Remitting Experimental Autoimmune Encephalomyelitis with Persistent Meningeal Inflammation and Subpial Demyelination in A/T SJL/J Mice
P177. Cigarette Smoke Exposure in Mice Enhances Myelin-Specific T Helper Responses in Peripheral Lymphoid Organs yet Attenuates the Severity of Experimental Autoimmune Encephalomyelitis
P178. It May Not Be Just "How Many Steps" You Take, But "How You Achieve Them" That is Important in Activity Monitoring of People with Multiple Sclerosis
P179. Lymphotoxin Alpha Overexpression in the Meninges Causes Lymphoid-Like Tissue Development and Subsequent Neurodegeneration
P180. MS-Associated Somatic Mutations in the RNA Binding Protein (RBP) Heterogeneous Nuclear Ribonucleoprotein A1 (A1) may Lead to Neurodegeneration
P181. Neuroprotective Effects of the Sphingosine 1 Phosphate Receptor 1/5 Modulator RP-101074 on Retinal Neurodegeneration and Visual Function in Light-Induced Photoreceptor Loss
P182. Asymptomatic Herpes Simplex Virus-Type 1 Infection Modulates Experimental Autoimmune Encephalomyelitis Onset and Severity
P183. Characterization of MS Brain Lesions Using Flow Cytometry and Histochemistry
P184. EMMPRIN is Critical for CCR2+ Monocytes Migration into EAE/MS Brains
P185. Impact of Dietary Methionine and Manipulation of Methionine Metabolism on T Lymphocyte Activation and Ability to Invade the CNS in Neuroinflammation
P186. Influence of PINK1 on Onset and Severity of Experimental Autoimmune Encephalomyelitis
P187. Investigating NLRP3 Inflammasome Activation and Regulation in Multiple Sclerosis and Experimentally-Induced Demyelination
P188. The Role of Ten Eleven Translocase 2 (TET2) in Regulating CNS Myeloid Cells during Experimental Autoimmune Encephalomyelitis
P189. Antibodies to the RNA Binding Protein hnRNP A1 Contribute to Ongoing Neuronal Cell Loss and Increased Markers of Necroptosis in Experimental Autoimmune Encephalomyelitis
P190. The Role of Neuronal CXCL13 Chemokine Expression in Multiple Sclerosis Pathology
P191. A Central Effect of Ponesimod on Neuroinflammation in a Pre-Clinical Model of Multiple Sclerosis
P192. A Role for Oligodendroglia RNA Binding Protein Dysfunction in the Pathogenesis of a Mouse Model of Multiple Sclerosis
P193. Angiotensin II Stimulation in Microglial Cell Pro-Inflammatory Response: Role in Multiple Sclerosis
P194. Drug Library Screen Identifies the Inhibitors for Induction of Toxic Astrogliosis
P195. Human CD4 Th17 Cells Cause Direct Damage to Oligodendrocytes Trough Glutamate Secretion
P196. Microglial BTK Signaling Regulates Immune-Mediated Cortical Demyelination
P197. microRNA-210 Regulates the Metabolic and Inflammatory Status of Primary Human Astrocytes
P198. RGC-32 Facilitates Reactive Astrocytosis in Experimental Autoimmune Encephalomyelitis by Maintaining a Mature Phenotype
Patient-Reported Outcomes and Quality of Life
P199. A Retrospective Analysis of the Association Between Insurance Level, DMT Usage, and Severity of Disease in Multiple Sclerosis Patients in Hawaii
P200. Addressing HRQoL in Children with MS
P201. Assessing the Impact of Disease Activity and Fatigue Symptom on Work Productivity and Activity Impairment in Patients with Relapsing Multiple Sclerosis
P202. Changes in Fatigue Status on the FSIQ-RMS Symptoms Domain in the Phase 3 OPTIMUM Study
P203. Drawing Out Experience: Novel Methods to Research the Experiences of People with Multiple Sclerosis and their Carers
P204. Evaluating the Impact of Fatigue Symptoms on Work Productivity and Activity Impairment using Longitudinal Data from the Phase III OPTIMUM study
P205. Investigating the Impact of Individual Disease-Modifying Therapies on Anxiety and Depression in Multiple Sclerosis
P206. Measuring the Symptoms and Impacts of Fatigue in Adults with Relapsing Multiple Sclerosis using a Novel Disease-Specific Scale: A Real-World Study in US Population
P207. Multiple Sclerosis and the Ability to Participate in Social Roles and Activities: Disease Impact Beyond Physical Disability
P208. Multiple Sclerosis, Cognition and the Ability to Participate in Social Roles and Activities: Disease Impact Beyond Physical Disability
P209. Nocturia and Fatigue in MS Patients
P210. Patient and Nurse Preferences for Sensoready® Autoinjector Pen Versus Other Autoinjectors in Multiple Sclerosis: Results from a Multicenter Survey
P211. Real-World Evidence on the Impact of PHQ-9 Depression Severity on Relapses in People with Multiple Sclerosis in the Multi-Center MS-CQI Collaborative Research Study
P212. Social, Demographic, and Socioeconomic Attributes of Persons with Multiple Sclerosis Experiencing Diminished Mental Health
P213. The Economic Burden Associated with Fatigue in Relapsing-remitting Multiple Sclerosis
P214. The Humanistic Burden Associated with Fatigue in Relapsing-remitting Multiple Sclerosis
P215. The impact of socioeconomic status on neurological outcomes in Multiple Sclerosis
© Copyright 2021 | Privacy |